tiprankstipranks
Trending News
More News >
Faes Farma SA (ES:FAE)
BME:FAE
Advertisement

Faes Farma (FAE) Price & Analysis

Compare
17 Followers

FAE Stock Chart & Stats


Faes Farma News

FAE FAQ

What was Faes Farma SA’s price range in the past 12 months?
Faes Farma SA lowest stock price was €3.27 and its highest was €4.73 in the past 12 months.
    What is Faes Farma SA’s market cap?
    Faes Farma SA’s market cap is €1.32B.
      When is Faes Farma SA’s upcoming earnings report date?
      Faes Farma SA’s upcoming earnings report date is Oct 30, 2025 which is in 42 days.
        How were Faes Farma SA’s earnings last quarter?
        Faes Farma SA released its earnings results on Aug 05, 2025. The company reported €0.168 earnings per share for the quarter, beating the consensus estimate of N/A by €0.168.
          Is Faes Farma SA overvalued?
          According to Wall Street analysts Faes Farma SA’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Faes Farma SA pay dividends?
            Faes Farma SA pays a Semiannually dividend of €0.138 which represents an annual dividend yield of 4.24%. See more information on Faes Farma SA dividends here
              What is Faes Farma SA’s EPS estimate?
              Faes Farma SA’s EPS estimate for its next earnings report is not yet available.
              How many shares outstanding does Faes Farma SA have?
              Faes Farma SA has 316,223,940 shares outstanding.
                What happened to Faes Farma SA’s price movement after its last earnings report?
                Faes Farma SA reported an EPS of €0.168 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.117%.
                  Which hedge fund is a major shareholder of Faes Farma SA?
                  Currently, no hedge funds are holding shares in ES:FAE

                  Faes Farma Stock Smart Score

                  Company Description

                  Faes Farma SA

                  Faes Farma, S.A., a pharmaceutical company, researches, develops, produces, and commercializes pharmaceutical products and raw materials in Spain and internationally. The company's product portfolio includes prescription drugs, generic drugs, over-the-counter (OTC) drugs, food supplements, baby foods, and other health products. It offers Actimag, a magnesium pidolate; Bilaxten, an anti-allergic; Bronquidiazina CR, an anti-infective; Claversal for ulcerative colitis and Crohn's disease; Dezacor, a corticoid; Dolotren, an anti-inflammatory; Dolotren Gel; Dynamogen, an anti-anorexic; Ferroprotina, an anti-anaemic; Hidroferol; Lipofen; Positon for dermatitis; strength builder products, such as Potenciator and Surmenalit; Pruina, a laxative; Robaxisal Compuesto, a muscle relaxant and analgesic; Trausan, a citicoline; Venosmil, a venous vasoprotector; Venosmil Gel; and Yendol, an anti-flu. The company also provides Bilastine, an antihistamine molecule for the treatment of allergic rhino conjunctivitis and urticarial; Calcifediol for bone metabolism; Deflazacort to treat osteoarticular disease; Hidrosmin for venous insufficiency; and Mesalazine to treat digestion problems. It also exports its products. Faes Farma, S.A. was founded in 1933 and is headquartered in Leioa, Spain.

                  Faes Farma (FAE) Earnings & Revenues

                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Almirall
                  Grifols
                  LABORATORIO REIG JOFRE
                  Laboratorios Farmaceuticos Rovi
                  Pharma Mar SA

                  Options Prices

                  Currently, No data available
                  ---
                  Popular Stocks
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis